Upgrade to SI Premium - Free Trial

Lantern Pharma (LTRN)

3.79 0.00 (0.00%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/12/26)

Latest Headlines

Lantern Pharma reports extended survival in lung cancer trial June 2, 2026 8:15 AM - StreetInsider Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer June 2, 2026 8:13 AM - BizWire Form 8-K Lantern Pharma Inc. For: Jun 01 June 2, 2026 6:06 AM - SEC Filing New to The Street Broadcasts Nationwide on Bloomberg Television Featuring "Opportunities To Consider(TM)" Across Artificial Intelligence, Healthcare Innovation, Fintech, Digital Assets, and Commoditie May 30, 2026 11:55 AM - StreetInsider New to The Street Broadcasts Episode 753 Today at 6:30 PM EST Across Bloomberg Television U.S., MENA, and Latin America Featuring Leaders in VR Defense Training, AI Streaming, Healthcare Innovation, a May 23, 2026 12:25 PM - StreetInsider Form D Lantern Pharma Inc. May 21, 2026 2:44 PM - SEC Filing Lantern Pharma receives FDA clearance for HARMONIC trial amendments May 19, 2026 7:30 AM - StreetInsider Lantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for HARMONIC™ Phase 2 Trial of LP-300 in Never-Smokers with NSCLC May 19, 2026 7:30 AM - BizWire Form SCHEDULE 13D/A Lantern Pharma Inc. Filed by: Bios Equity Partners, LP May 15, 2026 4:29 PM - SEC Filing Form 8-K Lantern Pharma Inc. For: May 15 May 15, 2026 4:13 PM - SEC Filing Form 10-Q Lantern Pharma Inc. For: Mar 31 May 15, 2026 4:10 PM - SEC Filing Lantern Pharma Reports First Quarter 2026 Financial Results and Provides Business Updates May 15, 2026 4:01 PM - BizWire Form 8-K Lantern Pharma Inc. For: May 12 May 14, 2026 5:27 PM - SEC Filing Form 4 Lantern Pharma Inc. For: May 12 Filed by: Schalop Lee Troy May 14, 2026 4:10 PM - SEC Filing Form 4 Lantern Pharma Inc. For: May 12 Filed by: KEYSER D JEFFREY May 14, 2026 4:10 PM - SEC Filing Lantern Pharma closes $9.25 million registered direct offering May 14, 2026 4:05 PM - StreetInsider Lantern Pharma closes $9.25 million registered direct offering May 14, 2026 4:05 PM - StreetInsider Lantern Pharma Inc. Announces Closing of up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor May 14, 2026 4:05 PM - BizWire Form 424B5 Lantern Pharma Inc. May 14, 2026 9:03 AM - SEC Filing Lantern Pharma raises up to $9.25 million in registered direct offering May 13, 2026 8:00 AM - StreetInsider Lantern Pharma Inc. Announces up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor May 13, 2026 8:00 AM - BizWire Lantern Pharma to Report First Quarter 2026 Operating & Financial Results on May 15th, 2026 May 11, 2026 4:30 PM - BizWire Lantern Pharma announces roadmap for withZeta.ai AI platform expansion May 7, 2026 9:01 AM - StreetInsider Lantern Pharma Unveils Roadmap for withZeta.ai — Industry-First, Multi-Agentic Co-Scientist Featuring Swarm Intelligence and Computational Biology Toolkit with the Launch of ZetaSwarm™ and ZetaOmi May 7, 2026 9:01 AM - BizWire Form 10-K/A Lantern Pharma Inc. For: Dec 31 April 30, 2026 6:17 AM - SEC Filing Lantern Pharma’s predictBBB.ai Evolves Into a Real-Time Large Quantitative Model (LQM) for Precision Molecular Intelligence — Comprehensive Small Molecule Characterization & Development Analyt April 29, 2026 8:50 AM - BizWire New to The Street Broadcasts Show #746 Tonight on Bloomberg Television 6:30PM EST Featuring NRx Pharma (NASDAQ:NRXP), Performance Golf, Lost Soldier Oil & Gas, Dr. Lee Gause, and CISO Global April 25, 2026 12:55 PM - StreetInsider CORRECTION: Join Lantern Pharma on April 30 for the First Public Demonstration of withZeta.ai - A Platform to Conquer Rare Cancers April 24, 2026 9:26 AM - StreetInsider Join Lantern Pharma on April 30 for the First Public Demonstration of with Zeta.ai - A Platform to Conquer Rare Cancers April 24, 2026 9:00 AM - StreetInsider Lantern Pharma to Debut Public Demonstration of withZeta.ai - A Platform to Conquer Rare Cancers on April 30 Following AACR 2026 Scientific Debut April 24, 2026 7:50 AM - BizWire Lantern Pharma schedules FDA meeting for LP-300 lung cancer drug April 20, 2026 8:05 AM - StreetInsider Emerging Data for Lantern Pharma’s Investigational Drug LP-300 Demonstrates 8.3-Month Median Progression-Free Survival in Patients with EGFR L858R Lung Cancer After Targeted Therapy Failure — With April 20, 2026 8:05 AM - BizWire RedChip's Biotech Investor Conference Replays Now Available April 20, 2026 8:04 AM - StreetInsider Form SCHEDULE 13D/A Lantern Pharma Inc. Filed by: Bios Equity Partners, LP April 16, 2026 3:48 PM - SEC Filing Lantern Pharma launches withZeta.ai commercial platform for cancer research April 14, 2026 8:36 AM - StreetInsider Lantern Pharma Launches withZeta.ai — the World’s First Multi-Agentic A.I. Co-Scientist for Rare Cancer Drug Discovery & Development — Subscriptions Now Open; Debut Events at Nasdaq MarketSi April 14, 2026 8:31 AM - BizWire Form 8-K Lantern Pharma Inc. For: Apr 09 April 10, 2026 8:00 AM - SEC Filing Form SCHEDULE 13G Lantern Pharma Inc. Filed by: SATTERFIELD THOMAS A JR April 3, 2026 10:53 AM - SEC Filing RedChip Showcases Public Companies Driving Biotech Innovation at April 16 Virtual Investor Conference April 2, 2026 8:46 AM - StreetInsider Lantern Pharma Invites Investors, Analysts & Shareholders to Experience the Future of Drug Discovery via a Live Demo of withZeta.ai — the World's First Multi-Agentic Co-Scientist for Rare C April 2, 2026 8:10 AM - BizWire Form 424B5 Lantern Pharma Inc. March 30, 2026 5:59 PM - SEC Filing Form 10-K Lantern Pharma Inc. For: Dec 31 March 30, 2026 5:46 PM - SEC Filing Form 8-K Lantern Pharma Inc. For: Mar 30 March 30, 2026 5:45 PM - SEC Filing Lantern Pharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates March 30, 2026 4:05 PM - BizWire Lantern Pharma denies false report about CEO departure March 27, 2026 7:23 PM - StreetInsider Lantern Pharma Confirms Panna Sharma Continues to Serve as President and CEO; Alerts Investors to False Third-Party Report March 27, 2026 7:23 PM - BizWire Lantern Pharma receives FDA clearance for pediatric brain cancer trial March 27, 2026 7:29 AM - StreetInsider Lantern Pharma and Starlight Therapeutics Announce FDA Clearance of IND for a Planned Phase 1 Pediatric CNS Cancer Trial of STAR-001 March 27, 2026 7:29 AM - BizWire RedChip AI Investor Conference Replays Now Available Highlighting Companies Driving Innovation Across the AI Ecosystem March 27, 2026 7:00 AM - StreetInsider Lantern Pharma to Report Fourth Quarter and Fiscal Year 2025 Operating & Financial Results on March 30th, 2026 at 4:30 p.m. ET March 23, 2026 4:30 PM - BizWire New to The Street Announces Broadcast of Show #739 on Bloomberg Television Across the U.S. at 6:30 PM EST March 21, 2026 1:55 PM - StreetInsider Full Article List